Yang DD, et al. – The prevalence of definitive therapy in elderly patients with intermediate–risk or high–risk disease was investigated. Results reported a significant association of older age with a decreased likelihood of receiving definitive therapy and an increased likelihood of receiving primary androgen deprivation therapy (ADT) in this national cohort of patients with intermediate–risk or high–risk prostate cancer. Definitive therapy was not administered in approximately 40% to 45% of patients aged ≥80 years. Given the dismal outcomes of conservatively managed unfavorable–risk prostate cancer, these findings were alarming.